Anyone surprised ?, page-78

Itsa, Nusinerson (spiranza) was developed in 2012 so if it is gen 2 it would have been one of the last gen 2 to be developed.
Some details on side effects is worth noting and understanding why ANP's drugs are at a standstill.
Like other antisense drugs, there is a risk of abnormalities in blood clotting and a reduction in platelets as well as a risk of kidney damage.^[2]
In clinical trials, people treated with nusinersen had an increased risk of upper and lower respiratory infections and congestion, ear infections, constipation, pulmonary aspiration, teething, and scoliosis. One infant in a clinical trial had severe lowering of salt levels and several had rashes. There is a risk that growth of infants and children might be stunted. In older clinical trial subjects, the most common adverse events were headache, back pain, and adverse effects from the spinal injection.^[2]
Some people may develop antibodies against the drug; as of December 2016 it was unclear what effect this might have on efficacy or safety.